$GILD QuantLogix Newsdesk · July 7, 2026 at 3:02 PM UTC

Kite, BBG Advanced Therapies Launch Mobile Leukapheresis Unit for GILD CAR-T Access

What happened

BBG Advanced Therapies announced a mobile leukapheresis center developed in collaboration with Kite, Gilead's oncology subsidiary, intended to extend CAR T-cell collection capabilities to patients living far from certified treatment centers. The initiative targets a longstanding logistical barrier in CAR-T delivery: the requirement that patients travel to certified apheresis centers before cell collection can begin. No financial terms were disclosed in the announcement.

The QL Read

GILD carries a composite signal of 77/100 and is up 4.44% on the session, outperforming a softening tape in which only 44.1% of issues are advancing. Whether the access-expansion initiative attracts sustained institutional interest remains to be seen against that constructive momentum backdrop.

Source: GlobeNewswire Inc. — "BBG Advanced Therapies Launches Mobile Leukapheresis Center, in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients" — 2026-07-07T14:00:00Z

Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.